Loïc Lebellec

Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)

Astrid Lièvre, Anthony Turpin, Isabelle Ray‐Coquard et al. · European Journal of Cancer · 2020 · 164 citations · Full text

Medicine, Infectious Diseases, Oncology +14

Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

David Adams, Michael Polydefkis, Alejandra González‐Duarte et al. · The Lancet Neurology · 2020 · 156 citations

Medicine, Neurology, Pharmacotherapy +14

Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)

Emmanuelle Bompas, Axel Le Cesne, Emmanuelle Tresch‐Bruneel et al. · Annals of Oncology · 2015 · 120 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF)

Loïc Lebellec, Bruno Chauffert, Jean‐Yves Blay et al. · European Journal of Cancer · 2017 · 56 citations

Medicine, Oncology, Surgery +13

Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE‐158 study

Do‐Youn Oh, Alain P. Algazi, Jaume Capdevila et al. · Cancer · 2023 · 56 citations · Full text

Medicine, Oncology, Pharmacotherapy +14